Pre-conference meeting: Sjögren's Genetics Network (SGENE).

Chair: Dr. Chris Lessard (Oklahoma Medical Research Foundation)

A live demonstration of the technique
Dr. Sandrine Jousse-Joulin (University of Brest Occidentale)

Gray scale and Colour Doppler scoring: How do we score?
Dr. Alojzija Hocevar (University Medical Centre Ljubljana)

Scoring together: an interactive online voting exercise 
Dr. Konstantina Delli / Dr. Jolien van Nimwegen / Dr. Alja Stel (University Medical Center Groningen)

Pre-conference course II | Beyond focus scores! A hands-on workshop on histological features of Sjögren's disease and computational pathology

Dr. Bert van der Vegt / Dr. Gwenny Verstappen / Dr. Frans Kroese (University Medical Center Groningen)

Challenging cases of Sjögren-associated histological features: Sharing first impressions

Challenging cases of Sjögren-associated histological features: Expert views and approaches

Assessment of lymphoepithelial lesions using digital image analysis and artifical intelligence

Welcome & opening

Prof. Dr. Hendrika Bootsma

Session 1: From a patient's point of view

Chairs: Dr. Alan Baer (National Institute of Dental and Craniofacial Research) & Dr. Sofie Blokland (University Medical Center Utrecht)

Session 1a: From a patient's point of view - invited speakers

Aligning Patient and Clinician Perspectives

Dr. Alan Baer (National Institute of Dental and Craniofacial
Research) & Ms. Kathy Hammitt (Sjögren's Foundation, USA) 

Optimizing Prevention and Management of Sjögren’s Disease Oral Complications: An Interprofessional Affair

Dr. Caroline Shiboski (University of California, San Francisco)

Life with Sjögren: more than meets the eye

Ms. Ana Vieira (Sjögren Europe)

O1.1 The Minimally Important Difference for the Xerostomia Inventory among Sjögren’s Disease Patients

Z. Assy (Academic Centre for Dentistry Amsterdam)

O1.2 Novel Tool ‘The Sjögren's Symptoms Card and my Positive Health Spider Web’

J. Koelewijn-Tukker (National Sjögren's Patients Association (NVSP))

Session 2: Glands and imaging

Chairs: Dr. Luca Quartuccio (University of Udine) & Dr. Valerie Devauchelle-Pensec (University of Brest Occidentale)

Session 2a: Glands and imaging

Imaging of Sjögren’s Disease with Special Reference to Ultrasound 

Dr. Sandrine Jousse-Joulin (University of Brest Occidentale)

O2.1 Stratifying Salivary Gland Secretory Hypofunction of Sjögren’s Syndrome Based on A Novel Ultrasonographic Scoring Model

Y. Mo (Sun Yat-sen Memorial Hospital, Sun Yat-sen University)

O2.2 Development of salivary gland organoids to study Sjögren’s disease

L. Meudec (University of Paris-Saclay)

O2.3 Harmonization of digital image analysis of salivary gland histological parameters in Sjögren’s disease

M. Rizzo (University of Udine)

O2.4 Ultra-high frequency ultrasound examination of labial salivary glands and lachrymal glands: diagnostic accuracy and prognostic value

G. Fulvio (University of Pisa)

Session 2c: Glands and imaging

Sjögren Syndrome and non-Sjögren Syndrome Dry Eye Patients Have Similar Transcriptional Expression Patterns Involving Immune Pathways in the Conjunctiva

Dr. Cintia de Paiva  (Baylor College of Medicine)

Session 3: Pathogenetic aspects I

Chairs: Dr. Christopher Lessard (Oklahoma Medical Research Foundation) & Dr. Sarah Pringle (University Medical Center Groningen)

Session 3a: Pathogenetic aspects I

Advancing Interceptive Medicine for Sjögren’s Disease Through Integrated ‘Omics’

Dr. Blake Warner (National Institute of Dental and Craniofacial Research)

O3.1 Labial salivary gland CD4+ T-cell composition in Sjögren’s Disease is heterogeneous and contains multiple cell differentiation states

D. Farris (Oklahoma Medical Research Foundation)

O3.2 IL-27 drives CD4 and CD8 T cell differentiation in lacrimal gland autoimmunity

I. Debreceni (University of Iowa)

O3.3 Transcriptomic profiling of Sjogren’s salivary glands identifies rheumatoid factor signatures associated with both follicular and extra-follicular responses

E. Pontarini (Queen Mary University of London)

O3.4 Rare deleterious variants in NFAT5 and PRKCD in three siblings with pediatric-onset Sjögren’s disease

G. Verstappen (University Medical Center Groningen)

Session 3c: Pathogenetic aspects I - abstract session II

Chairs: Dr. Andreas Goules (National and Kapodistrian University of Athens) & Dr. Marjan Versnel (University Medical Center Rotterdam)

O3.5 TYK2 is required for salivary and lacrimal gland inflammation in a mouse model of Sjogren's disease

S. Lieberman (University of Iowa)

O3.6 Amlexanox inhibits type I interferon production and suppresses B cell differentiation in vitro: a potential novel therapeutic option for Sjögren's syndrome and other systemic inflammatory diseases

A. Björk (Karolinska Institute)

O3.7 Single-cell RNA-sequencing of PBMCs confirms the central role of anti-SSA antibodies and its association with Interferon-stimulated genes in the systemic expression of Sjögren’s disease

G. Urbanski (University of California, San Francisco)

O3.8 Lysosome-associated membrane protein 3 amplifies type I IFN response by inducing ectopic TLR7 expression in salivary gland epithelial cells

H. Nakamura (Sapporo Medical University School of Medicine)

Session 4: Trials and tools

Chairs: Dr. Maureen Rischmueller (University of Adelaide) & Prof. Dr. Hendrika Bootsma (University Medical Center Groningen)

Session 4a: Trials and tools

Trial Design and Tools for Sjögren’s Disease

Dr. Suzanne Arends (University Medical Center Groningen)                

O4.1 Dazodalibep, a CD40L Antagonist, in Subjects with Sjögren’s Disease having Moderate-to-Severe Systemic Disease Activity: Full Crossover Results from a Phase 2, Randomized, Double-Blind, Placebo-Controlled, Proof of Concept Study

C. Baldini (University of Pisa)

O4.2 Iscalimab (CFZ533) in patients with Sjögren’s Disease: Week 24 efficacy and biomarker results of a randomized, placebo-controlled, phase 2b dose-ranging study

X. Mariette (University of Paris-Saclay)

O4.3 Clinical efficacy and patient-reported outcomes (PROs) in anti-Ro/Sjögren’s syndrome–related antigen A (SSA) antibody–positive patients with active systemic lupus erythematosus (SLE) treated with deucravacitinib in the phase 2 PAISLEY trial

B. Fisher (University of Birmingham)

O4.4 Large-scale discovery proteomics in Sjögren's disease: delineating treatment response and pathophysiological insights from the RepurpSS-I trial

V. Baloche (University Medical Center Utrecht)

Session 5: Extra-glandular involvement

Chairs: Dr. Xavier Mariette (University of Paris-Saclay) & Dr. Chiara Baldini (University of Pisa)

Session 5a: Extra-glandular involvement

Dysautonomia in Sjogren's Disease

Dr. Brent Goodman (Metrodora Institute)

O5.1 The burden and characteristics of neurological symptoms in patients with Sjögren disease

C. Bouillot (Sjögren Europe)

O5.2 Evidence-Based Guidelines for Sjögren’s Disease Peripheral Nervous System Manifestations

R. Fox (Scripss Research Institute)

O5.3 Sleep disturbance, Depression and Fatigue in Sjogren's disease: the impact on occupational health

B. Carneiro Cintra (University of São Paulo)

O5.4 Real-World fatigue variability in Sjögren’s Syndrome

J. Chow (Newcastle University)

Session 5c: Extra-glandular involvement

Fatigue in Sjögren’s Disease

Dr. Wan-Fai Ng (Newcastle University

12:45 - 14:30

Executive Project Management Team meeting NECESSITY consortium - on invitation only.

Chair: Dr. Xavier Mariette (University of Paris-Saclay)

Session 6: Pathogenic aspects II

Chairs: Dr. Athanasios Tzioufas (National and Kapodistrian University of Athens) & Dr. Marie Wahren-Herlenius (Karolinska Institute)

Session 6a: Pathogenic aspects II

Deciphering the Cross-Talk Between Lymphocytes and Epithelium in Sjögren’s Disease

Dr. Gaetane Nocturne (University of Paris-Saclay)

O6.1 Cytoplasmic accumulation of mitochondrial dsRNAs by aberrant SUV3 expression activates PKR in monocytes of childhood Sjögren’s disease

S. Cha (University of Florida)

O6.2 Transcriptional dysregulation in Sjögren’s disease through the lens of mitophagy

J. Ice 

O6.3 Harnessing cell energy metabolism to suppress salivary gland inflammation in Sjogren Syndrome: role of glycolysis in metabolic reprogramming and regulation of epithelial cell inflammation

S. Colafrancesco (Humanitas University)

O6.4 Differentiation of human pluripotent stem cells (iPSCs) into human salivary gland epithelial progenitors

X. Wang (Beijing Tiantan Hospital, Capital Medical University)

Session 7: Outstanding abstracts presentations

Chairs: Dr. Divi Cornec (University of Brest Occidentale) & Dr. Zana Brkic (Erasmus Medical Center)

O7.1 Sexual experience and functioning in female and male patients with primary Sjögren’s Disease: a qualitative study

D. Rebel (University Medical Center Groningen)

O7.2 Spatial Transcriptomics Implicates Glandular Cell Involvement in Pathophysiology of Sjögren’s Disease

C. Lessard (Oklahoma Medical Research Foundation)

O7.3 Stratification of Sjögren’s disease, based on symptoms, clinical and routine biological data, is supported by distinct pathophysiological pathway

Y. Nguyen (AP-HP Hospital Beaujon)

O7.4 cGAS-STING pathway activation drive Type-I IFN in Sjögren’s Disease

B. Warner (National Institute of Dental and Craniofacial Research)

Session 8:  Classification and stratification 

Chairs: Dr. Joël van Roon (Newcastle University) & Dr. Caroline Shiboski (University of California, San Francisco)

Session 8a:  Classification and stratification                 

Sjögren’s Disease Endotypes: Towards Precision Medicine

Dr. Sara McCoy (University of Wisconsin)

O8.1 Genome-wide Association Study of Ro/SSA+ and Ro/SSA- Sjögren’s cases in the Sjögren’s Genetic Network (SGENE) demonstrates divergent genetic architecture in patient subphenotypes

A. Rasmussen (Oklahoma Medical Research Foundation)

O8.2 The weight of immunoblot testing in Sjögren’s Syndrome: does the quantitative titer of autoantibodies influence the severity of disease onset?

S. Fonzetti (University of Pisa)

O8.3 Damage accrual in Sjögren’s disease over 5 years: the GIRRCS Sjogren’s disease cohort experience

A. Marino (Campus Biomedico of Rome)

O8.4 Mucosal associated lymphoid tissue lymphoma predictors in primary Sjogren’s Disease by data driven analysis in harmonized patients

A. Goules (National and Kapodistrian University of Athens)

Session 9: Looking forward!

Chairs: Dr. Gaetane Nocturne (APHP- Hopital Bicêtre) & Dr. Benjamin Fisher (University of Birmingham)

Session 9a: Looking forward! - invited speaker

Molecular Pathology for Patients’ Stratification in Sjogren’s Disease: Where Are We?

Dr. Michele Bombardieri (Queen Mary University of London)

O9.1 Ultrasound guided core-needle biopsy of the unswollen parotid gland is a reliable technique in the work-up of primary Sjögrens’ syndrome

H. Achten (Ghent University)

O9.2 Diagnosing Sjogren's Syndrome: A Multi-modal Deep Learning Approach with Histopathologic Images and Clinical Data

D. Cornec (University of Brest Occidentale)

O9.3 A high polygenic risk score is associated with SSA antibody positivity in primary Sjögren’s syndrome

C. Fugmann (University of Uppsala)

O9.4 Deconstruction and Reconstruction of Sjögren’s Disease: AMP-AIM Partnership

A. Rasmussen (Oklahoma Medical Research Foundation)

Closing remarks, awards ceremony & announcement 17^th ISSjD